ABSTRACT The f3-adrenoceptor-blocking and class II1 effects of sotalol were assessed in 1 1 patients with inducible orthodromic reciprocating tachycardia. Serum sotalol concentration, maximum exercise heart rate, and electrophysiologic study data were obtained at control, at the /3-adrenoceptor-blocking dosage 
SOTALOL is a newer antiarrhythmic agent with both ,3-adrenoceptor-blocking and class III electrophysiologic activity. 1-6 Although its antiarrhythmic efficacy had been documented for ventricular arrhythmias,7-11 the efficacy and safety of oral sotalol therapy for the supraventricular tachyarrhythmias complicating Wolff-Parkinson-White (WPW) syndrome have not been assessed systematically. The /3-adrenoceptorblocking effects of sotalol should be advantageous in the treatment of the reciprocating tachycardias of WPW syndrome primarily by slowing conduction and prolonging refractoriness of the atrioventricular (AV) connections, isolated 3-adrenoceptor blockade may fail to control and may even accelerate the ventricular response rate to atrial fibrillation. [12] [13] [14] [15] In distinction to other,-adrenoceptor-blocking agents, the additional class III effects of sotalol should contribute to efficacy in the treatment of the reciprocating tachycardias of WPW syndrome primarily by prolonging refractoriness of the accessory connection. Furthermore, class III activity can also reduce the ventricular response rate to atrial fibrillation. 16 Therefore, a major determinant of the balance between efficacy and safety of sotalol therapy in patients with the WPW syndrome will be the dose ranges over which these two classes of electrophysiologic effects are manifest.
The purpose of this study was to determine the dosage range over which the /3-adrenoceptor-blocking and class III electrophysiologic effects of sotalol become manifest and to determine the relative contributions of these effects to the safety and antiarrhythmic efficacy of sotalol in patients with WPW syndrome.
CIRCULATION THERAPY AND PREVENTION-ARRHYTHMIA Methods
Protocol. Eleven adult patients with WPW syndrome and drug-resistant, supraventricular tachyarrhythmias consented to participate in this study. The study protocol (figure 1) was approved by our Institutional Ethics Review Board. All medications were discontinued for five half-lives and a baseline exercise test and catheter electrophysiologic study were performed. Oral sotalol therapy was then introduced at a dosage of 80 mg twice daily. The dosage was doubled every 3 days until antiarrhythmic efficacy was documented, side effects occurred, or a maximum dosage of 640 mg twice daily was reached. Measurement of trough serum sotalol levels and exercise testing were repeated on the third day of each dosage. The electrophysiologic study was repeated at the 160 mg twice daily and subsequent dosage levels.
Study population. Seven men and four women with supraventricular tachyarrhythmias secondary to WPW syndrome participated. Their mean age was 33 + 11 years (range 19 to 50). Ten patients had no other structural heart disease. One had coexistent arrhythmogenic right ventricular dysplasia. These patients had had unsuccessful therapy with 3.3 ± 1.7 antiarrhythmic drugs (range 1 to 5). All patients had inducible, sustained, orthodromic reciprocating tachycardia.
Exercise testing. Symptom-limited, treadmill exercise tests were performed according to a Bruce protocol.17 Maximum exercise heart rates were determined from the average of 10 consecutive beats. The sotalol dosage resulting in physiologic /3-adrenoceptor blockade was defined as that which caused minimal further reduction in the maximum exercise heart rate. Specifically, the dosage in use when the maximum heart rate was reduced by less than 10% from the previous exercise test was termed the ,B-adrenoceptor-blocking dosage. Electrophysiologic studies. Surface electrocardiographic leads I, aVF, and V1 were recorded simultaneously with intracardiac electrograms from the high lateral right atrium, proximal and distal coronary sinus, His interval at which A2 (V2) failed to produce a propagated response. The atrial (ventricular) functional refractory period was the shortest A1A2 (V1V2) interval created during determination of the atrial (ventricular) refractory curve. The accessory AV connection anterograde effective refractory period was the longest A1A2 interval that did not result in ventricular preexcitation as manifest by loss of the surface QRS delta wave. The accessory connection retrograde effective refractory period was defined as the longest V1V2 interval that did not result in atrial preexcitation as manifest by normalization of the retrograde atrial activation sequence. Accessory connection refractory periods were determined by pacing and recording close to the location of the accessory connection.
AV nodal effects were assessed by changes in the AH interval during atrial pacing at a cycle length of 600 msec and by changes in the AV nodal functional and effective refractory periods. The latter were determined by the extrastimulus technique after 8 beat trains of atrial pacing at a cycle length of 600 msec. The AV nodal effective refractory period was the longest A1A2 interval at which A2 was not conducted to the ventricles via the normal conduction system. The AV nodal functional refractory period was the shortest H1H2 obtainable by atrial extrastimulation. AV nodal refractory periods could be determined only in patients with conduction via the normal system at extrastimulus coupling intervals less than the accessory connection effective refractory period.
Each study also included attempted induction of both orthodromic reciprocating tachycardia and atrial fibrillation. The tachyarrhythmias were noninducible if no more than four ventricular cycles could be produced, were sustained if their duration exceeded 30 sec, and were nonsustained if five or more cycles of less than 30 sec duration were produced.
Long-term therapy. Antiarrhythmic efficacy was defined as prevention of induction of sustained orthodromic reciprocating tachycardia along with a minimum preexcited RR interval during atrial fibrillation of 300 msec or greater. Patients with an antiarrhythmic response were discharged on sotalol. Follow-up consisted of a clinical evaluation, 12-lead ECG, 24 hr ambulatory ECG recording, and determination of trough serum sotalol levels at 3 month intervals.
Biochemical analyses. Serum samples were assayed for sotalol by high-performance liquid chromatography. An internal standard (soterenol: 0.1 ml of solution containing 0.01 mg/ml) was added to serum. Briefly, 1 ml of serum was extracted with the solution containing 7 mg of ethyl acetate and 0.1 ml of 2M Bicine (Calbiochem, La Jolla, CA) at pH 9.3. The organic phase was decanted and the serum reextracted. The organic phases were pooled and evaporated to dryness. Sotalol and soterenol were separated by a C-18 Microbondapak (Waters) reversephase column with a mobile phase consisting of 35% methanol/0.0015M (NH4)2 HPO4. The day-to-day variation on a 1 p.g/ml sample was 5% (mean 0.95 + 0.05 gtg/ml).
Statistical analysis. Continuous data are presented as mean + 1 SD. Dose-response data were compared at baseline, at the dosage producing physiologic /3-adrenoceptor blockade, and at the maximum well-tolerated dosage. These comparisons included only patients assessed at all three dosage levels. Significance was determined by two-way analysis of variance and Duncan's multiple range test. The null hypothesis was rejected at p < .05. Concentration-response relationships were examined by fitting individual data points to five mathematical models (linear, exponential, power series, Emax, and sigmoid Emax) with the NONLIN curve fitting program.18 When the best fit was obtained with an Emax model, the maximum effect (Emax) and the concentration producing 50% maximum effect (EC50) were calculated.
Results
/3-Adrenoceptor blockade. The dosages producing physiologic /8-adrenoceptor blockade were 160 mg twice daily for eight patients and 320 mg twice daily for three patients (407 ± 149 mg/day). The mean trough serum sotalol concentration on this dosage was 1.4 ± 0.5 jug/ml. Dosages exceeding those required forf/-adrenoceptor blockade were assessed in the nine patients without antiarrhythmic efficacy at the /3-adrenoceptor-blocking dosage. The maximum well-tolerated dosage was 320 mg twice daily for five of these nine patients and the maximum dosage of 640 mg twice daily was reached in the other four (924 ± 337 mg/day). The mean trough serum sotalol concentration on this dosage was 3.2 ± 1.3 gg/ml. Dosage-response relationships. The effects of sotalol dosage on sinus and AV nodal electrophysiologic variables are shown in figure 2. The mean maximum exercise heart rate was significantly decreased from control (167 ± 14 beats/min) by the ,B-adrenoceptor-blocking dosage (125 ± 15 beats/min) and was decreased significantly further by the maximum well-tolerated dosage (108 ± 14 beats/min). The mean resting heart rate was significantly decreased from control (76 ± 17 beats/min) by the ,3-adrenoceptor-blocking dosage (58 ± 10 beats/min). However, it was not reduced significantly further by the maximum well-tolerated dosage (53 ± 10 beats/min). The mean AH interval was significantly increased over control (100 ± 26 msec) by the /8-adrenoceptor-blocking dosage (137 ± 35 msec). No further change was produced by the maximum well-tolerated dosage (138 ± 37 msec). AV nodal effective and functional refractory periods could be determined in four patients. These refractory periods were significantly increased by the /3-adrenoceptor-blocking dosage but were not further increased by the maximum well-tolerated dosage (figure 2).
The effects of sotalol dosage on measurements of class III activity are illustrated in figure 3 . The mean anterograde accessory connection effective refractory period was significantly increased over control (272 ± 41 msec) by the /3-adrenoceptor-blocking dosage (324 + 52 msec) and was increased significantly further by the maximum well-tolerated dosage (364 ± 37 msec). These changes were paralleled by increases in atrial and ventricular effective refractory periods, retrograde accessory connection refractory period, and QT interval (figure 3). Concentration-response relationships. Figure 4 relates serum sotalol concentration to percent reduction in maximum exercise heart rate (left panel) and percent increase in anterograde accessory connection effective refractory period (right panel). These data were fit to the five mathematical models. The maximum exercise heart rate concentration-response relationship was best described by the Emax model illustrated (r = .63). The Emax was a 41% reduction in exercise heart rate, and the sotalol EC50 was 0.7 ,g/ml. The anterograde accessory connection effective refractory period concentration-response relationship was best described by a linear model over the concentration range tested (r = .70). Linear relationships were also observed between sotalol concentration and the increase in atrial and ventricular effective refractory periods, retrograde dromic reciprocating tachycardia. The /3-adrenoceptor-blocking dosage of sotalol prevented the induction of sustained orthodromic reciprocating tachycardia in six patients and prevented the induction of any orthodromic reciprocating tachycardia in two. The latter two patients also demonstrated control of the ventricular response rate to induced atrial fibrillation and did not receive higher dosages of sotalol. The remaining nine patients were assessed on the maximum well-tolerated dosage. This higher dosage prevented the induction of sustained orthodromic reciprocating tachycardia in two more patients and prevented induction of any orthodromic reciprocating tachycardia in two additional patients. Overall, sotalol prevented the induction of sustained orthodromic reciprocating tachycardia in eight patients (73%) and prevented the induction of any orthodromic reciprocating tachycardia in four patients (36%).
The cumulative percentage of the study patients who achieved antiarrhythmic efficacy is plotted as a function of serum sotalol concentration in figure 6 . These data fit a sigmoid Emax model (r = .99) with an Emax of 74% of the patients and a sotalol EC50 of 1.6 ug/ml. The 95% confidence interval for the EC50 describing the relationship between maximum exercise heart rate and serum sotalol concentration (0.17 to 1.31 ,g/ml) did not overlap with that for the relationship between antiarrhythmic efficacy and serum sotalol concentration (1.44 to 1.78 gg/ml).
Long-term therapy. The eight patients with antiarrhythmic efficacy were discharged on long-term oral sotalol therapy. Two patients received 160 mg twice daily, three patients received 320 mg twice daily, and three patients received 640 mg twice daily. Thus the mean daily dosage was 800 + 420 mg. None of these patients has had a recurrence of sustained reciprocating tachycardia during 15 + 12 months of follow-up. However, one patient has had further symptomatic tachyarrhythmias. Both atrial fibrillation with a controlled ventricular response rate and torsade de pointes ventricular tachycardia have occurred after heavy alcohol consumption.
Two patients have been withdrawn from sotalol because of side effects. One patient had dysphoric symptoms after 2 months of therapy and one patient complained of fatigue and nausea after 18 months of therapy. Both subsequently required accessory connection ablation for control of their tachyarrhythmias.
Discussion
General electrophysiologic effects of sotalol. After sotalol was introduced as a ,B-adrenoceptor-blocking The eight patients with an antiarrhythmic response to oral sotalol received long-term therapy. Long-term absence of recurrent, sustained reciprocating tachycardia was well predicted by electrophysiologic study. Significant side effects occurred in 25% of these patients but were usually the typical benign adverse effects of /8-adrenoceptor blockade that have been previously reported.56 An association between sotalol therapy and torsade de pointes ventricular tachycardia has been reported57 and was also noted in this study. This association is not unexpected considering the potent class III activity of sotalol.
Limitations. The purpose of this investigation was to determine the dosage ranges over which the t3-adrenoceptor-blocking and class III effects of sotalol become manifest and to determine the relative contributions of these effect to the safety and antiarrhythmic efficacy of sotalol in patients with WPW syndrome. Both classes of electrophysiologic effect may be manifest in all cardiac tissues. Nevertheless, regional differences in expression of effects should permit assessment in vivo of the relative /3-adrenoceptor-blocking and class III activities of sotalol. The refractory periods of the atrium, ventricle, and accessory connection and the QT interval during atrial pacing provide measures of class III activity minimally influenced by /3-adrenoceptor-blocking effects. Similarly, the sinus heart rate response to exercise and the AH interval during atrial pacing provide measures of,-adrenoceptor-blocking activity minimally influenced by class III effects. These in vivo measures are frequently used for this purpose.7 9- 
